SCHEMBL2524368

SCHEMBL2524368

O=c1ncccn1Cc1ccc(Br)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.44
▸ EP300 Q09472 1/20 0.39
▸ CREBBP Q92793 1/20 0.39
▸ KAT2A Q92830 1/20 0.39
▸ KAT2B Q92831 1/20 0.39
▸ KLKB1 P03952 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ DBH P09172 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ S1PR2 O95136 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ TRPA1 O75762 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11704469 0.77 ALDH1A1 (0.46) KAT2BSMN1; SMN2MAPTDBHKDM4E
SCHEMBL19513462 0.76 MAPT (0.56) KAT2BSMN1; SMN2MAPTKDM4ES1PR2
SCHEMBL19501369 0.75 KMT2A (0.43) DGAT1KLKB1MAPTKMT2AEGLN1
SCHEMBL11687658 0.75 CYP19A1 (0.50) GAAKMT2AEGLN1
SCHEMBL2523932 0.75 DGAT1 (0.41) DGAT1EP300CREBBPKAT2AKAT2B
SCHEMBL15331766 0.69 ENPP2 (0.45) DGAT1KLKB1KDM4EKMT2AHTT
SCHEMBL15332032 0.69 KLKB1 (0.37) DGAT1KLKB1SMN1; SMN2MAPTKMT2A
SCHEMBL31637527 0.67 GRM2 (0.41) SMN1; SMN2KDM4EALDH1A1KMT2ALMNA
SCHEMBL29348967 0.67 GRM2 (0.41) SMN1; SMN2KDM4EALDH1A1KMT2ALMNA
SCHEMBL11486023 0.67 PKM (0.71) SMN1; SMN2ALDH1A1GAAL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251173-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2011-10-13 — — US disclosed
US-20110251173-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2011-10-13 — — US disclosed
US-20110251173-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2011-10-13 — — US disclosed
WO-2011121350-A1 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS ASTRAZENECA AB (SE) 2011-10-06 — — WO disclosed
WO-2011121350-A1 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS ASTRAZENECA AB (SE) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251173-A1 CHEMICAL COMPOUNDS DGAT1, DGAT2, SLC5A1 DGAT1 1/4885EP300 286/4885CREBBP 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback